NASDAQ:GLYC - GlycoMimetics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.75 -0.26 (-2.00 %)
(As of 04/24/2019 04:00 PM ET)
Previous Close$13.01
Today's Range$12.63 - $13.06
52-Week Range$8.29 - $19.20
Volume110,787 shs
Average Volume235,107 shs
Market Capitalization$550.40 million
P/E RatioN/A
Dividend YieldN/A
Beta2.76
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Price / Sales27,520.24
Book Value$4.76 per share

Profitability

Net Income$-48,270,000.00

Miscellaneous

Employees50
Market Cap$550.40 million
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) announced its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.02. View GlycoMimetics' Earnings History.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for GlycoMimetics.

What price target have analysts set for GLYC?

5 brokerages have issued 12-month price objectives for GlycoMimetics' stock. Their predictions range from $20.00 to $35.00. On average, they expect GlycoMimetics' stock price to reach $25.50 in the next year. This suggests a possible upside of 100.0% from the stock's current price. View Analyst Price Targets for GlycoMimetics.

What is the consensus analysts' recommendation for GlycoMimetics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.

What are Wall Street analysts saying about GlycoMimetics stock?

Here are some recent quotes from research analysts about GlycoMimetics stock:
  • 1. HC Wainwright analysts commented, "We base our $23 price target on probability-adjusted forecasts for uproleselan in AML as well as rivipansel in SCD VOC. We use the net present value of our revenue forecast through 2027, apply a 60% POS for AML and a 70% POS for SCD 4x price/sales multiple for AML, and estimated 2019 year-end net cash of $3.11 per share, to arrive at our price target. Our P/S multiple of 4x is inline with GlycoMimetics’ peers that range between 2-5x." (4/12/2019)
  • 2. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (3/7/2019)

Has GlycoMimetics been receiving favorable news coverage?

News coverage about GLYC stock has been trending positive on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GlycoMimetics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 60)
  • Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)
  • Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
  • Mr. Henry Flanner, VP of Technical Operations

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by many different of retail and institutional investors. Top institutional investors include JGP Global Gestao de Recursos Ltda. (0.02%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Helen M Thackray, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.

Which major investors are buying GlycoMimetics stock?

GLYC stock was acquired by a variety of institutional investors in the last quarter, including JGP Global Gestao de Recursos Ltda.. View Insider Buying and Selling for GlycoMimetics.

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $12.75.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $550.40 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is http://www.glycomimetics.com.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]


MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  427
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel